http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2585378-C1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_215927f82607de4510c5d445fac21d3a |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 |
filingDate | 2014-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2016-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2db9f65e4fcfbb497cb73903afee2d72 |
publicationDate | 2016-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2585378-C1 |
titleOfInvention | Solid dosage form for oral administration containing combination of vildagliptin and gliquidone |
abstract | FIELD: chemistry. n SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a pharmaceutical composition, made in form of a tablet, produced by direct compression. As active ingredients tablet contains a DPP-IV inhibitor vildagliptin in amount of 1.3-86 wt% and gliquidone or its pharmaceutically acceptable salt in an amount of 0.8-68.5 wt%. Active ingredients make up from 2.1 to 98 wt% of composition. Present invention also includes a multilayer tablet and a multilayer tablet with modified release, produced by direct compression method. Their core contains vildagliptin, and external layer contains gliquidone. Binding substance used is cellulose or derivatives thereof, and substance retarding vildagliptin release from core of multilayer tablet is preferably hydroxypropylcelllose in amount of 15-35 wt% of core. Invention also enables to treat a category of patients suffering type 2 diabetes mellitus accompanied by chronic renal disease. n EFFECT: invention provides stability of tablet prepared by direct compression, containing claimed composition. n 19 cl, 36 ex |
priorityDate | 2014-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 214.